Tiragolumab With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage SCLC
1. Median PFS and OS between the tiragolumab and control arms were similar 2. Treatment-related AEs that were grade 3/4...
1. Median PFS and OS between the tiragolumab and control arms were similar 2. Treatment-related AEs that were grade 3/4...
1. Overall pathologic complete response to treatment of triple-negative breast cancer with a non-anthracycline regimen was 58% 2. The estimated...
1. The median overall survival was 12.1 months in the erdafitinib group and 7.8 months in the chemotherapy group, with...
1. Progression-free survival was not reached in the selpercatinib group and was 16.8 months in the control group, with an...
1. Progression-free survival was 6.3 months for the amivantamab–chemotherapy group, 8.3 months for the amivantamab–lazertinib–chemotherapy group, and 4.2 months for...
1. A greater percentage of patients who received concurrent stereotactic radiation therapy with antibody-drug conjugates manifested severe levels of radiation...
1. The progression-free survival was 24.8 months in the selpercatinib group vs 11.2 months in the control group (chemotherapy ±...
1. Median overall survival and progression-free survival were greater in the tebentafusp group compared to the control group. 2. Adverse...
1. Median progression-free survival was 11.4 months in the amivantamab–chemotherapy group and 6.7 months in the chemotherapy group with HR...
1 .The progression-free survival in berzosertib with topotecan vs topotecan alone was not statistically significant, but the overall survival was...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.